Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | TBIO | Common Stock | 0 | Jun 9, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | TBIO | Stock Option (right to buy) | 0 | Jun 9, 2022 | Common Stock | 0 | Direct | F1 |
Id | Content |
---|---|
F1 | On June 9, 2022, the Reporting Person was granted 20,630 restricted stock units and options to purchase 30,945 shares of common stock of Codex DNA, Inc. (the "Issuer") under the Issuer's Outside Director Compensation Policy. However, the Reporting Person has declined the awards described above and any future annual awards until further notice. As a result, the transfer of such restricted stock units and options to purchase common stock did not in fact take place. Accordingly, as of June 15, 2022, the Reporting Person did not own any restricted stock units or options to purchase shares of common stock in the Issuer. |